Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Nature Communications

Volumn 7, Issue , 2016, Pages

  Van Emburgh, Beth O ^a,b,c   Arena, Sabrina ^a,c   Siravegna, Giulia ^a,c   Lazzari, Luca ^a,c   Crisafulli, Giovanni ^a,c   Corti, Giorgio ^a   Mussolin, Benedetta ^a   Baldi, Federica ^a,c   Buscarino, Michela ^a   Bartolini, Alice ^a   Valtorta, Emanuele ^d   Vidal, Joana ^e   Bellosillo, Beatriz ^e   Germano, Giovanni ^a   Pietrantonio, Filippo ^f   Ponzetti, Agostino ^g   Albanell, Joan ^e   Siena, Salvatore ^d,h   Sartore Bianchi, Andrea ^d   Di Nicolantonio, Federica ^a,c   Montagut, Clara ^e   Bardelli, Alberto ^a,c   more..

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e HOSPITAL DEL MAR   (Spain)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g MOLINETTE HOSPITAL   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CHLOROPLAST DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FIRTECAN; GENOMIC DNA; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANTIBODY; CANCER; CELLS AND CELL COMPONENTS; DNA; DRUG RESISTANCE; MUTATION; PROTEIN; TUMOR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLONAL EVOLUTION; DNA SEQUENCE; EXTRACELLULAR MATRIX; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE N RAS; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COLORECTAL TUMOR; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MUTATION; ONCOGENE RAS; PROTO ONCOGENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CLONAL EVOLUTION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, ERBB-1; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85006074206     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13665     Document Type: Article

References (45)

1. McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med 7, 283ra254 (2015).
2. Miller, C. A. et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput. Biol. 10, e1003665 (2014).
3. Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338-345 (2013).
4. Diaz, L. A. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
5. Burrell, R. A. & Swanton, C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol. Oncol. 8, 1095-1111 (2014).
6. Van Cutsem, E. et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658-1664 (2007).
7. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
8. Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S. & Bardelli, A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 4, 1269-1280 (2014).
9. Dienstmann, R., Salazar, R. & Tabernero, J. Overcoming resistance to anti-EGFR therapy in colorectal cancer. Am. Soc. Clin. Oncol. Educ. Book 35, e149-e156 (2015).
10. Montagut, C. et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 18, 221-223 (2012).
11. Arena, S. et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin. Cancer Res. 21, 2157-2166 (2015).
12. Morelli, M. P. et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann. Oncol. 26, 731-736 (2015).
13. Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 827 (2015).
14. Bhang, H. E. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440-448 (2015).
15. Porter, S. N., Baker, L. C., Mittelman, D. & Porteus, M. H. Lentiviral and targeted cellular barcoding reveals ongoing clonal dynamics of cell lines in vitro and in vivo. Genome Biol. 15, R75 (2014).
16. Hobor, S. et al. TGFa and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. Clin. Cancer Res. 20, 6429-6438 (2014).
17. Yun, J. et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325, 1555-1559 (2009).
18. Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27-47 (2016).
19. Fakih, M. G. Metastatic colorectal cancer: current state and future directions. J. Clin. Oncol. 33, 1809-1824 (2015).
20. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
21. Esposito, C. et al. The S492R EGFR ectodomain mutation is never detected in KRAS wild type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol. Ther. 14, 1143-1146 (2013).
22. Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39 (2009).
23. Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability-an evolving hallmark of cancer. Nat. Rev. Mol. Cell. Biol. 11, 220-228 (2010).
24. Chen, L. L. et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 64, 5913-5919 (2004).
25. Camidge, D. R., Pao, W. & Sequist, L. V. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat. Rev. Clin. Oncol. 11, 473-481 (2014).
26. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
27. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
28. Bardelli, A. et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658-673 (2013).
29. Yonesaka, K. et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86 (2011).
30. Misale, S. et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med. 6, 224ra226 (2014).
31. Boland, C. R. & Goel, A. Microsatellite instability in colorectal cancer. Gastroenterology 138, 2073-2087 (2010).
32. Mouradov, D. et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res. 74, 3238-3247 (2014).
33. Kahlert, C. et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J. Biol. Chem. 289, 3869-3875 (2014).
34. Thakur, B. K. et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24, 766-769 (2014).
35. Garcia-Olmo, D. C. et al. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res. 70, 560-567 (2010).
36. Oddo, D. et al. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer. Cancer Res. 76, 4504-4515 (2016).
37. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
38. Pietrantonio, F. et al. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann. Oncol. 25, 404-408 (2014).
39. Wong, N. A. et al. RAS testing of colorectal carcinoma-a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. J. Clin. Pathol. 67, 751-757 (2014).
40. Follenzi, A. & Naldini, L. Generation of HIV-1 derived lentiviral vectors. Methods Enzymol. 346, 454-465 (2002).
41. Whitehead, R. H., Macrae, F. A., St Sohn, D. J. & Ma, J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J. Natl Cancer Inst. 74, 759-765 (1985).
42. Kent, W. J. BLAT-the BLAST-like alignment tool. Genome Res. 12, 656-664 (2002).
43. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403-410 (1990).
44. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589-595 (2010).
45. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).